NorthSea Therapeutics raises $40m to develop NASH drug

Dutch biotech NorthSea Therapeutics has raised around $40 million in a series B financing round to help it develop novel strategies to treat the fatty liver disease known as NASH.<

MiNA’s gene-activating tech wins an AstraZeneca alliance

NHS pressures are threatening vital research, says report

Transgene starts trials of ‘digital’ cancer vaccine with NEC

Incyte's JAK inhibitor for GVHD fails phase 3 trial

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.

Melinta is latest antibiotics biotech to file for bankruptcy...

US biotech Melinta Therapeutics has become the latest antibiotics specialist to file for bankruptcy, after courts said it could use its lenders’ cash to keep operating until a possible sale